<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133780</url>
  </required_header>
  <id_info>
    <org_study_id>42017</org_study_id>
    <nct_id>NCT03133780</nct_id>
  </id_info>
  <brief_title>Sedation During Spinal Anesthesia</brief_title>
  <official_title>A Comparison of the Sedative Effect of Ketamine and Midazolam During Spinal Anaesthesia for Elective Unilateral Inguinal Hernia Repair: A Randomized Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients during spinal anesthesia should be sedated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia offers a number of advantages to both the patient and the physician.&#xD;
      However, patients are often reluctant to remain awake during a procedure. Sedation has been&#xD;
      shown to increase patient satisfaction during regional anesthesia and may be considered as a&#xD;
      means to increase the patient's acceptance.Therefore, provision of adequate sedation is&#xD;
      important if the advantages of spinal anesthesia are to be fully appreciated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2018</start_date>
  <completion_date type="Actual">March 7, 2020</completion_date>
  <primary_completion_date type="Actual">March 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for the onset of sedation in minutes assessed by modified observer's assessment of alertness/sedation score</measure>
    <time_frame>90 min after the tested drug adminisred</time_frame>
    <description>assessed by modified observer's assessment of alertness/sedation score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Sedation During Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>dormicum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients aged from 18 to 40 years old undergoing elective unilateral inguinal&#xD;
             hernia repair with no neurological, cardiovascular and hepato-renal abnormalities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: younger than 18 or older than 40.&#xD;
&#xD;
          -  Psychatric or neurological disorders.&#xD;
&#xD;
          -  Cardiovascular disorders.&#xD;
&#xD;
          -  Coagulation disorders.&#xD;
&#xD;
          -  Contraindications to neuraxial block (allergy to L.A, peripheral neuropathy, prior&#xD;
             spine surgery).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seham M Moeen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut Univerisity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Assuit University</name>
      <address>
        <city>Assiut</city>
        <state>Asyut</state>
        <zip>71516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Seham Mohamed Moeen Ibrahim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

